Related Experiment Video
Updated: Apr 19, 2026

Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
Published on: March 20, 2018
Formation of DNA adducts by ellipticine and its micellar form in rats - a comparative study
Marie Stiborova1, Zuzana Manhartova2, Petr Hodek3
1Department of Biochemistry, Faculty of Science, Charles University, Albertov 2030, CZ-128-40 Prague 2, Czech Republic. stiborov@natur.cuni.cz.
Abstract:
The requirements for early diagnostics as well as effective treatment of cancer diseases have increased the pressure on development of efficient methods for targeted drug delivery as well as imaging of the treatment success. One of the most recent approaches covering the drug delivery aspects is benefitting from the unique properties of nanomaterials. Ellipticine and its derivatives are efficient anticancer compounds that function through multiple mechanisms. Formation of covalent DNA adducts after ellipticine enzymatic activation is one of the most important mechanisms of its pharmacological action. In this study, we investigated whether ellipticine might be released from its micellar (encapsulated) form to generate covalent adducts analogous to those formed by free ellipticine. The (32)P-postlabeling technique was used as a useful imaging method to detect and quantify covalent ellipticine-derived DNA adducts. We compared the efficiencies of free ellipticine and its micellar form (the poly(ethylene oxide)-block-poly(allyl glycidyl ether) (PAGE-PEO) block copolymer, P 119 nanoparticles) to form ellipticine-DNA adducts in rats in vivo. Here, we demonstrate for the first time that treatment of rats with ellipticine in micelles resulted in formation of ellipticine-derived DNA adducts in vivo and suggest that a gradual release of ellipticine from its micellar form might produce the enhanced permeation and retention effect of this ellipticine-micellar delivery system.
Insights
Encapsulating anticancer drug ellipticine in nanoparticles (PAGE-PEO) effectively forms DNA adducts in vivo, similar to free ellipticine. This micellar delivery system shows promise for cancer treatment, potentially leveraging the enhanced permeation and retention effect.
Area of Science:
- Nanomedicine
- Pharmacology
- Biochemistry
Background:
- Effective cancer treatment requires efficient drug delivery and imaging methods.
- Nanomaterials offer unique properties for targeted drug delivery.
- Ellipticine is an anticancer compound that forms DNA adducts.
Purpose of the Study:
- To investigate if micelle-encapsulated ellipticine releases to form DNA adducts in vivo.
- To compare the efficacy of micellar ellipticine versus free ellipticine in forming DNA adducts.
- To explore the potential of nanoparticle-based ellipticine delivery for cancer therapy.
Main Methods:
- Utilized the (32)P-postlabeling technique for detecting and quantifying DNA adducts.
- Administered free ellipticine and micellar ellipticine (PAGE-PEO nanoparticles) to rats in vivo.
- Compared the formation of ellipticine-DNA adducts between the two delivery methods.
Main Results:
- Micellar ellipticine successfully formed ellipticine-derived DNA adducts in rats.
- The formation of DNA adducts by micellar ellipticine was comparable to free ellipticine.
- Demonstrated the in vivo efficacy of nanoparticle-encapsulated ellipticine.
Conclusions:
- Ellipticine released from micelles can form DNA adducts, similar to free ellipticine.
- The PAGE-PEO micellar system is a viable delivery method for ellipticine.
- Gradual release from micelles may enhance drug delivery via the EPR effect.

